Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy for COVID-19 Infection
NCT04482686Phase 1Completed
- Sponsor
- ProgenaBiome
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ivermectin and doxycycline in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ProgenaBiome. Primary endpoints: Time to Non-Infectivity by RT-PCR at 6 months, Time to Symptom progression as measured by NEWS scoring system at 6 months and 3 more. Started Dec 2020; status: completed.
02
Drugs
ivermectindoxycycline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04482686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482686.